Utility of an Immunotherapy Trial in Evaluating Patients with Presumed Autoimmune Epilepsy
Neurol 82:1578-1586, Toledano, M.,et al, 2014
Intensive Care Unit Admission in Multiple Sclerosis
Neurol 82:2112-2119, Marrie, R.A.,et al, 2014
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Addition of Hyperacute MRI Aids in Patient Selection, Decreasing the Use of Endovascular Stroke Therapy
Stroke 45:467-472, Wisco, D.,et al, 2014
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
NEJM 370:911-920, Zhou, Q.,et al, 2014
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Recommendations for the Management of Cerebral and Cerebellar Infarction with Swelling
Stroke 45:1222-1238, Wijdicks, E.F.M.,et al, 2014
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke
NEJM 370:1091-1100,1159, Juttler, E.,et al, 2014
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013
Mycoplasma Pneumoniae Infection: Neurologic Complications
www.MedLink.com, Oct, Greenlee, J.E., 2013
Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Interdependence and Contributions of Sun Exposure and Vitamin D to MRI Measures in Multiple Sclerosis
JNNP 84:1075-1081, 1066, Zivadinov, R.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Clinical Spectrum of CNS Aquaporin-4 Autoimmunity
Neurol 78:1179-1185, Kim, S.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013
Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013
Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013
Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013
Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013
Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013
Aspergillus Meningitis: A Rare Clinical Manifestation of Central Nervous System Aspergillosis
J Infect 66:218-238, Antinori, S.,et al, 2013
Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balos Concentric Lesions
Intern Med 52:1517-1521, Masuda, H.,et al, 2013
Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin
BMC Neurol 12:131, Novak, P.,et al, 2012
Emerging Subspecialties in Neurology: Neuroimmunology
Neurol 79:e178-e180, Clardy, S., 2012
Brain Atrophy is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL
Stroke 38:1786-1790, Jouvent, E.,et al, 2012
Painful Tonic Spasm in Neuromyelitis Optica
Arch Neurol 69:1026-1031, Kim, S.M.,et al, 2012